2020
04/29/2020: Congratulation to Dr. Aoyuan Cui for that her paper entitled “The effects of B1344, a novel fibroblast growth factor 21 analog, on nonalcoholic steatohepatitis in nonhuman primates” published in Diabetes. The study characterizes beneficial effects of a novel FGF21 analog B1344 on lowering hepatic steatosis, fibrosis and inflammation, and on protecting against the progression of nonalcoholic steatohepatitis in rodents and nonhuman primates. This study was finished through a collaboration with Tasly Pharmaceutical Co. Ltd and Kunming Biomed International (KBI), and is highlighted by Commentary: Kleinert M, Muller TD. A new FGF21 analog for the treatment of fatty liver disease. Diabetes. 2020, 69(8).
05/06/2020: Congratulation to Aoyuan Cui for receiving Excellent Merit Student award (三好学生标兵), SINH, CAS, and Yaqian Xue for receiving Merit Student award (三好学生), SINH, CAS.
06/05/2020: Congratulation to Dr. Jinyun Bai for that his paper entitled “Thrombospondin1 improves hepatic steatosis in diet-induced insulin-resistant mice and are associated with hepatic fat content in humans” published in EBioMedicine.
This study sought to discover novel secreted proteins in humans that are associated with hepatic fat content using unbiased proteomic profiling strategy, and reveal how the identified thrombospondin 1 (Thbs1) modulates lipid metabolism and hepatic steatosis. The study characterizes pharmacological administration of recombinant human Thbs1 attenuates hepatic steatosis in diet-induced obese mice. Mechanistically, hepatic CD36 is necessary for Thbs1 protein or peptide mimetic ABT-526 to inhibit SREBP-1 cleavage and target lipogenic gene expression. This study was finished through a collaboration with Dr. Xin Gao at Zhongshan Hospital of Fudan University.
06/13/2020: Li Lab attended American Diabetes Association 80th Scientific Sessions (ADA)'s Virtual 80th Scientific Sessions, June 12-16, 2020, Chicago, IL.
06/15/2020: Dr. Yu Li was invited to give a talk (Symposium) entitled “Nutrient sensing and metabolic regulation in the liver” at the session of Chinese Diabetes Society Symposium-Novel Antidiabetic Approaches and Potential Targets, American Diabetes Association 80th Scientific Sessions (ADA)'s Virtual 80th Scientific Sessions, June 12-16, 2020, Chicago, IL.
06/22/2020: Congratulation to Aoyuan Cui for passing PhD thesis defense. Thank all the thesis defense committee members.
08/24/2020: Drs. Dongguang Xiao and Cuiying from the College of Biotechnology, Tianjin University of Science and Technology were invited to visit the Li Lab, which is hosted by Dr. Yu Li at Shanghai Institute of Nutrition and Health, CAS, Shanghai. Both sides discussed and agreed to initiate a collaborated research project on the mechanistic study of Baijiu (Chinese liquor)’s flavor compounds on ethanol metabolism and human health, and the development of optimized Baijiu brewing technology
11/07/2020: The Li Lab attended virtual meeting of the 15th Conference of the Chinese Society of Lipids and Lipoproteins.
11/26/2020: Dr. Yu Li was invited to give a talk entitled “Hormonal regulation of hepatic metabolism and nonalcoholic fatty liver disease in nonhuman primates” at the Chinese Diabetes Association (CDS)’s 24th scientific meeting in Suzhou.
11/29/2020: Welcome Shuang Wei to join the Li Lab as a PhD graduate student.
12/10/2020: Congratulations to Dr. Aoyuan Cui and Dong Ding for their review article entitled “Regulation of hepatic metabolism and cell growth by the ATF/CREB family of transcription factor” to be accepted for publication in Diabetes.
12/10/2020: Congratulation to Dr. Aoyuan Cui for receiving the award of “Shanghai Postdoctoral Fellowship Grant” (上海市博士后日常经费资助) funded by Shanghai Bureau of Human Resources and Social Security.
12/17/2020: Join the Li Lab’s Christmas party in Shanghai Disney Resort, where fun will be had and memories will be made. Goodbye 2020, welcome the New Year of 2021.
